%0 Journal Article
%A Castellano, Daniel
%A Maroto, José Pablo
%A Espinosa, Enrique
%A Grande, Enrique
%A Bolós, M Victoria
%A Llinares, Julia
%A Esteban, Emilio
%A González Del Alba, Aranzazu
%A Climent, Miguel Angel
%A Arranz, Jose Angel
%A Méndez, Mª José
%A Fernández Parra, Eva
%A Antón-Aparicio, Luis
%A Bayona, Cristina
%A Gallegos, Isabel
%A Gallardo, Enrique
%A Samaniego, Luz
%A García Donas, Jesús
%T Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
%D 2017
%U http://hdl.handle.net/10668/11225
%X A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. To evaluate the effectiveness and safety of sunitinib in patients with advanced or mRCC in routine clinical practice. Retrospective pooled analysis of clinical data from three observational and prospective studies carried out between 2007 and 2011 in 33 Spanish hospitals. Tumor response, Progression-free survival (PFS) and overall survival (OS), and main sunitinib-related toxicities were registered. 224 patients were analyzed. Median PFS 10.6 months (95% CI: 9.02-12.25), median OS 21.9 months (95% CI: 17.2-26.6). Objective response rate (ORR) 43.8% (95% CI: 36.8-50.7). Median time to PR was 3.8 months (95% CI: 3.86-5.99) and to CR 8.2 months (95% CI: 4.75-9.77). The most common ≥ grade-3 AEs were asthenia/fatigue (18.7%), hand-foot syndrome (6.2%), hypertension (5.8%) and neutropenia (4.8%). Hand-foot syndrome, diarrhea and mucositis were confirmed as independent predictors for PFS and/or OS in a multivariate analysis (p 
%K Effectiveness
%K routine clinical practice
%K safety
%K sunitinib
%~